CIP2A deficiency in mice leads to resistance to DMBA (7,12-dimethylbenz[a]anthracene)-induced basal-like breast cancer formation17, and inhibition of CIP2A induces cell cycle arrest, promotes apoptosis or cellular senescence, and exhibits therapeutic efficacies in vitro and in vivo26,27. This evidence concerns the gene CIP2A and breast cancer.